Therapeutic Enzyme‐Responsive Nanoparticles for Targeted Delivery and Accumulation in Tumors

An enzyme-responsive, paclitaxel-loaded nanoparticle is described and assessed in vivo in a human fibrosarcoma murine xenograft. This work represents a proof-of-concept study demonstrating the utility of enzyme-responsive nanoscale drug carriers capable of targeted accumulation and retention in tumor tissue in response to overexpressed endogenous enzymes.

[1]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[2]  P. Couvreur,et al.  Design of folic acid-conjugated nanoparticles for drug targeting. , 2000, Journal of pharmaceutical sciences.

[3]  R. Hynes,et al.  Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors , 1988, The Journal of cell biology.

[4]  Ti-Hsuan Ku,et al.  Enzyme‐Directed Assembly of a Nanoparticle Probe in Tumor Tissue , 2013, Advanced materials.

[5]  J. Marotta,et al.  Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery , 2002, The Journal of pharmacy and pharmacology.

[6]  P. Low,et al.  Selective targeting of malignant cells with cytotoxin-folate conjugates. , 1994, Journal of drug targeting.

[7]  Miriam Scadeng,et al.  Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival , 2010, Proceedings of the National Academy of Sciences.

[8]  Michael E. Hahn,et al.  Polymerization of Protecting-Group-Free Peptides via ROMP. , 2013, Polymer chemistry.

[9]  Roger Y Tsien,et al.  Tumor imaging by means of proteolytic activation of cell-penetrating peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Ling,et al.  Modeling the development of metastases from primary and locally recurrent tumors: comparison with a clinical data base for prostatic cancer. , 1993, Cancer research.

[11]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[12]  E. Lin,et al.  Fluorogenic Enzyme-Responsive Micellar Nanoparticles. , 2012, Chemical science.

[13]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[14]  Shigeo Sato,et al.  Anti‐tumor Efficacy of Paclitaxel against Human Lung Cancer Xenografts , 1997, Japanese journal of cancer research : Gann.

[15]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[16]  P. Schiff,et al.  Promotion of microtubule assembly in vitro by taxol , 1979, Nature.

[17]  Bielawski,et al.  Highly Efficient Ring-Opening Metathesis Polymerization (ROMP) Using New Ruthenium Catalysts Containing N-Heterocyclic Carbene Ligands C.B. is grateful to the National Science Foundation for a pre-doctoral fellowship. The authors thank Dr. Matthias Scholl for providing catalysts 4 a and 4 c. , 2000, Angewandte Chemie.

[18]  R. Crystal,et al.  Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. , 2001, Cancer research.

[19]  Galya Orr,et al.  Enzyme-directed assembly of nanoparticles in tumors monitored by in vivo whole animal imaging and ex vivo super-resolution fluorescence imaging. , 2013, Journal of the American Chemical Society.

[20]  H. Jin,et al.  Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.

[21]  R. Grubbs,et al.  Mechanism and activity of ruthenium olefin metathesis catalysts. , 2001, Journal of the American Chemical Society.

[22]  R. Tsien,et al.  Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases , 2010, Proceedings of the National Academy of Sciences.

[23]  P. Choyke,et al.  Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? , 2013, Theranostics.

[24]  Erkki Ruoslahti,et al.  Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.

[25]  P. Low,et al.  Folate receptor-targeted drugs for cancer and inflammatory diseases. , 2004, Advanced drug delivery reviews.

[26]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[27]  F. Sanda,et al.  Recent advances in ring-opening metathesis polymerization, and application to synthesis of functional materials , 2010 .

[28]  P. Low,et al.  Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. , 1995, Biochimica et biophysica acta.

[29]  S. Rabbani,et al.  Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects , 2007, Anti-cancer drugs.

[30]  M. Gilson,et al.  Peptides Displayed as High Density Brush Polymers Resist Proteolysis and Retain Bioactivity , 2014, Journal of the American Chemical Society.

[31]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[32]  J. Black,et al.  Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. , 1998, Cancer research.

[33]  R. Weissleder,et al.  Enzyme-targeted fluorescent imaging probes on a multiple antigenic peptide core. , 2006, Journal of medicinal chemistry.

[34]  S. Celikoglu,et al.  Bronchoscopic intratumoral chemotherapy of lung cancer. , 2008, Lung cancer.

[35]  Susan M. Chang,et al.  Intratumoral chemotherapy. Commentaries , 1995 .

[36]  R. Schiffelers,et al.  RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  Nathan C. Gianneschi,et al.  Stimuli-Responsive Nanomaterials for Biomedical Applications , 2014, Journal of the American Chemical Society.

[38]  D. Ribatti,et al.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.

[39]  C. Slugovc.  The Ring Opening Metathesis Polymerisation Toolbox , 2004 .

[40]  Gloria S. Huang,et al.  Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice , 2006, Clinical Cancer Research.

[41]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[43]  R. Grubbs,et al.  Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands. , 1999, Organic letters.

[44]  Y. Rustum,et al.  Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. , 2000, Cancer research.

[45]  R Weissleder,et al.  Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. , 2001, Radiology.

[46]  M. North,et al.  The synthesis and ring-opening metathesis polymerization of peptide functionalized norbornenes , 1999 .

[47]  J. Reddy,et al.  Folate-targeted chemotherapy. , 2004, Advanced drug delivery reviews.

[48]  P. Trail,et al.  Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[50]  M A Horton,et al.  The alpha v beta 3 integrin "vitronectin receptor". , 1997, The international journal of biochemistry & cell biology.

[51]  Robert H. Grubbs,et al.  A Versatile Precursor for the Synthesis of New Ruthenium Olefin Metathesis Catalysts , 2001 .

[52]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[53]  Sang-Oh Yoon,et al.  Inhibitory Effect of Selenite on Invasion of HT1080 Tumor Cells* , 2001, The Journal of Biological Chemistry.

[54]  R. Grubbs,et al.  The development of L2X2Ru=CHR olefin metathesis catalysts: an organometallic success story. , 2001, Accounts of chemical research.

[55]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[56]  C. Slugovc,et al.  The ROMP toolbox upgraded , 2010 .

[57]  R. Grubbs,et al.  Synthesis of Norbornenyl Polymers with Bioactive Oligopeptides by Ring-Opening Metathesis Polymerization , 2000 .

[58]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.